– Positive Interim Analysis of the FALCON Study Paves the Way for KL1333 Development –
Third Quarter Summary
Important events July – September 2024
- In July, Abliva announced a positive outcome of the interim analysis of the 24-week data of the FALCON study with KL1333, increasing the probability of a positive readout upon completion of the full study.
- Following the positive outcome of the interim analysis, Abliva was provided with additional proceeds of SEK 42 million before transaction costs through the conversion of the convertible bonds pledged in the capital raise earlier this year.
Financial information
July-September 2024*
- Net revenues: SEK 0 (0)
- Other operating income: SEK 0 (0)
- Loss before tax: SEK 19,541,000 (32,942,000)
- Loss per share before dilution: SEK 0.01 (0.03)
- Diluted loss per share: SEK 0.01 (0.03)
January-September 2024*
- Net revenues: SEK 0 (0)
- Other operating income: SEK 290,000 (2,783,000)
- Loss before tax: SEK 63,474,000 (70,260,000)
- Loss per share before dilution: SEK 0.05 (0.07)
- Diluted loss per share: SEK 0.05 (0.07)
* APM Alternative performance measures, see definition on page 20.
The complete Interim report is available for download below and through Abliva’s website www.abliva.com.